Physician profile

Ron Feldman

Dermatology · Atlanta, GA

NPI 1316123821

$28,603.43

in general payments reported to CMS, 2019-2025

9 companies · none reported in 2025

Payments by year

General payments by program year, as reported to CMS.

What the payments were for

Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.

View as a table
Payment typeAmount (2023-2025)
Consulting Fee$9,120.00
Travel and Lodging$837.96
Food and Beverage$234.20

Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.

Who reported paying

General payments only, as reported to CMS. Product names cover 2023-2025.

CompanyGeneral paymentsYearsTop products
Astrazeneca Uk Limited $8,387.16 2020-2023 Fasenra
Janssen Research & Development, LLC $7,440.00 2021-2022
Argenx US, INC. $5,625.00 2022-2023 Vyvgart
Galderma Laboratories, L.P. $5,138.76 2019-2021
Grifols, S.A. $2,000.00 2021-2022
Incyte Corporation $12.51 2022

3 companies reported research payments only; those appear in the research section below.

Drugs and devices associated with these payments

CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.

If you want to bring it up

Most clinicians are glad to talk about this. A respectful way in:

These are normal questions. A good clinician will welcome them.

Share this page

Payment summary

Ron Feldman

$28,603.43

in general payments reported 2019-2025

Years
2019-2023
Top company
Astrazeneca Uk Limited

https://glasscript.com/doctor/742080/ron-feldman

Source: CMS Open Payments, program years 2019-2025. Payments are legal and often routine.

Keep an eye on this page

Get an email when the next June refresh changes this page. No account needed.

Watch this doctor

Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.